ライフサイエンスコーパス: PLGA

1 PLGA 50/50 microspheres encapsulating ~5% w/w leuprolide

2 PLGA has been traditionally characterized by its molecul

3 PLGA NPs were found non-uniformly distributed on the epi

4 PLGA-b-PEG copolymer was synthesized and characterized b

5 PLGA-b-PEG NPs with desirable size, polydispersity, and

6 PLGA-b-PEG-NH2 and PLGA-b-mPEG NPs were prepared by nano

7 To date, about 20 PLGA-based formulations have been approved by the U.S.

8 taining 10% plasticizer and either 60 or 50% PLGA prolonged survival from 27 to 70 days in a GBM xeno

9 -transmission electron microscopy revealed a PLGA core coated with one or several concentric lipid bi

10 In summary, a PLGA-b-PEG-b-PLGA sol-gel has loading and release capaci

11 in reduction in TGF-beta expression, thus, a PLGA microsphere encapsulating PD-1 antagonist peptides

12 apsulating PD-1 antagonist peptides A12 (A12@PLGA) was further prepared to activate the host immune r

13 used for the conjugation with ascorbic acid (PLGA-b-PEG-Asc) to facilitate SVCT2 mediated transportat

14 A)/poly (d)(,)(l)(-)lactic-co-glycolic acid (PLGA) (75:25 w/w) or PHB as encapsulants.

15 osan shell and poly lactic-co-glycolic acid (PLGA) core for enhancing localized chemo-radiotherapy to

16 es: PEGylation and Polylactic glycolic acid (PLGA) microencapsulation.

17 the surface of poly-lactic-co-glycolic acid (PLGA) nanoparticles for the protection of a candidate dr

18 oved pegylated poly lactic-co-glycolic acid (PLGA) nanoparticles loaded with anticancer microRNAs (mi

19 Lycopene-loaded polylactic-co-glycolic acid (PLGA) NPs were prepared by the same method.

20 e-modified polylactic acid-co-glycolic acid (PLGA)-Chitosan nanoparticle (CSNP) for integrin alphavbe

21 ne glycol-poly lactic acid-co-glycolic acid (PLGA-PEG) polymeric nanoparticles (ARV-NPs) showed promi

22 ed Scl-Ab via poly(lactic-co-glycolic) acid (PLGA) microspheres (MSs) was compared at experimentally-

23 Poly(d,l-lactic-co-glycolic) acid (PLGA) nanoparticles containing phenolic extract of guabi

24 capsulated in poly(lactic-co-glycolic) acid (PLGA)-based nanoparticles (NPs) induce robust and durabl

25 ionic lipid-poly(lactide-co-glycolide) acid (PLGA) hybrid nanoparticles as antigen delivery carriers

26 g comprised of poly(lactic-coglycolic acid) (PLGA) nanofibers embedded in a poly(epsilon-caprolactone

27 er), a 50:50 poly (lactic-co-glycolic acid) (PLGA) (sheath layer) and a gelatin (intermediate layer)

28 yl-terminated poly(lactic-co-glycolic acid) (PLGA) allowed encapsulation of DSP into biodegradable na

29 arriers using poly(lactic-co-glycolic acid) (PLGA) and PLGA-polyethylene glycol (PLGA-PEG) polymers t

30 ly degradable poly(lactic-co-glycolic acid) (PLGA) and reactive oxygen species (ROS)-degradable poly(

31 w/w TMZ in poly(lactic acid-glycolic acid) (PLGA) and showed reliable release of high dose TMZ for a

32 LPHNPs) with poly (lactic-co-glycolic acid) (PLGA) core and lipid layer containing docetaxel and clin

33 ists of a poly(D,L-lactic-co-glycolic acid) (PLGA) fiber layer sandwiched between two poly(epsilon-ca

34 Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable FDA approved polymer and widely

35 accommodated poly(lactic-co-glycolic acid) (PLGA) microparticulate systems that controlled the relea

36 Here, two poly(lactic-co-glycolic acid) (PLGA) microsphere formulations encapsulating the model s

37 te loaded poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres (Sunb-malate MS) with a particle size

38 4 weeks from poly(lactic-co-glycolic acid) (PLGA) microspheres embedded in a poly(N-isopropylacrylam

39 biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres encapsulating a model luteinizing hor

40 d within the poly (lactic-co-glycolic acid) (PLGA) nanoparticle, which was then encapsulated into the

41 state inside poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PTX-MB@PLGA NPs).

42 ated in poly-(D, L-lactic-co-glycolic acid) (PLGA) nanoparticles adjuvanted with polyinosinic:polycyt

43 onstrate that poly(lactic-co-glycolic acid) (PLGA) nanoparticles carrying rapamycin, but not free rap

44 widely used poly (lactic-co-glycolic acid) (PLGA) nanoparticles contained in slow-release drug formu

45 Copolymer poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with SA-2 provided a sustaine

46 t based on poly(dl-lactic-co-glycolic acid) (PLGA) nanoparticles modified with the cationic surfactan

47 the peptide, poly(lactic-co-glycolic acid) (PLGA) nanoparticles were surface-modified with BAR and s

48 prepared poly(lactic acid-co-glycolic acid) (PLGA) nanoparticles with a PEGylated surface decorated w

49 entation over poly(lactic-co-glycolic acid) (PLGA) nanoparticles.

50 biodegradable poly(lactic-co-glycolic acid) (PLGA) NPs in a range of sizes (120-440nm) utilizing a mi

51 cently-tagged poly(lactic-co-glycolic acid) (PLGA) NPs were loaded with BODIPY, a fluorophore, and pe

52 e coating for poly(lactic-co-glycolic acid) (PLGA) NPs.

53 y assembling poly (lactic-co-glycolic acid) (PLGA) particles loaded with thrombin and MnO(2) nanoshee

54 hat inhalable poly(lactic-co-glycolic acid) (PLGA) particles of sildenafil prolong the release of the

55 antoin loaded poly(lactic-co-glycolic acid) (PLGA) particles to improve delivery to intracellular tar

56 s composed of poly(lactic-co-glycolic acid) (PLGA) that can encapsulate IPV along with stabilizing ex

57 s composed of poly(lactic-co-glycolic acid) (PLGA) with bright, spectrally defined quantum dots (QDs)

58 made from poly(D,L-lactic co glycolic acid) (PLGA), and can be used as a guiding reference to formula

59 and employed poly(lactic-co-glycolic acid) (PLGA)-based nanoparticle formulation for delivery.

60 unctions: (i) poly(lactic-co-glycolic acid) (PLGA, P) serving as the main delivery platform, (ii) pol

61 ol)-block-poly(D,L-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) sol-gels have been extensively resear

62 ol)-block-poly(d,l-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) thermosensitive gel (g-E).

63 ene glycol)-b-poly(lactic-co-glycolic acid); PLGA-PEG-PLGA) for increasing the retention of RNA nanop

64 hane solution of polylatic-co-glyclic acids (PLGA) and emulsified in a polyvinyl alcohol (PVA) and Na

65 Additionally, PLGA-b-PEG-Asc NPs resulted in significantly higher biod

66 ted the effect of intravenously-administered PLGA nanoparticles on the gut-liver axis under condition

67 After 7 days of administration, PLGA NP showed a higher brain bioavailability of bevaciz

68 Free extract and PLGA nanoparticles were effective inhibitors of Listeria

69 The muPL height and PLGA concentration had major effects on drug release, to

70 In summary, PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels may safely enable pre-clinica

71 clinical research on PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels that has focused on paclitaxe

72 PLGA-b-PEG-NH2 and PLGA-b-mPEG NPs were prepared by nanoprecipitation metho

73 NIH/3T3 cells as compared to plain PLGA and PLGA-b-mPEG NPs.

74 ing poly(lactic-co-glycolic acid) (PLGA) and PLGA-polyethylene glycol (PLGA-PEG) polymers to generate

75 optic neuropathy (bITON) showed that PPS and PLGA MP-mediated delivery of EPO-R76E provided therapeut

76 argeting is achieved by coating FDA-approved PLGA-PEG NP with the peptide sequence RGD, which binds w

77 readily apparent by the absence of approved PLGA-based generic products, limiting access to affordab

78 actors for tuning droplet/particle sizes are PLGA concentrations and the flow rates of dispersed and

79 As PLGA microparticles went through structural changes, the

80 drugs and drug loaded plain PLGA as well as PLGA-b-mPEG NPs.

81 In summary, a PLGA-b-PEG-b-PLGA sol-gel has loading and release capacities for EpoB

82 summary, PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels may safely enable pre-clinical evaluation

83 earch on PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels that has focused on paclitaxel will be upd

84 y(D,L-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) sol-gels have been extensively researched for syst

85 y(d,l-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) thermosensitive gel (g-E).

86 a new, multispectral approach for barcoding PLGA, which enables simultaneous, quantitative analysis

87 The developed biodegradable PLGA/PEG paste formulation augments high-density bone de

88 Both PLGA and PPS MPs enabled sustained release of EPO-R76E,

89 on of unique PLGA polymers, such as branched PLGA.

90 s provides a unique profile of each branched PLGA.

91 ameters have not been described for branched PLGA polymers.

92 parameters for characterization of branched PLGA polymers and the validation of these parameters usi

93 ion of these parameters using known branched-PLGA standards.

94 ped and validated using a series of branched-PLGA standards, and it was used to determine the branchi

95 b-A (Sub-A-mPEG) was further encapsulated by PLGA.

96 dulation of the inflammatory response by CaP/PLGA nanoparticle-mediated siRNA delivery could be a pro

97 wed similar trends as found with acid capped PLGA but with a longer lag time before release.

98 ease, release of leuprolide from acid-capped PLGA microspheres appeared to be controlled initially by

99 a higher molecular weight, ester end-capped PLGA displayed an osmotically induced/pore diffusion mec

100 Release of leuprolide from the end-capped PLGA showed similar trends as found with acid capped PLG

101 First, triblock copolymers of PEG-CNA-PLGA are synthesized and then formulated into polymer na

102 s do not get encapsulated within the PEG-CNA-PLGA nanoparticles.

103 netration potential of eucalyptus oil coated PLGA-chitosan double walled nanogels.

104 The ZWC-coated PLGA NPs showed pH-dependent surface charge profiles and

105 rison with uniaxial PLGA (50:50) and coaxial PLGA (50:50) (sheath)-gelatin (core) fibers was observed

106 ompound I-NP)] in poly(lactide-coglycolide) (PLGA) was developed that shows sustained maintenance of

107 A deeper understanding of complex PLGA formulations can be achieved with these new charact

108 on the cell surface, we used DAT-conjugated PLGA nanoparticles (NDAT) in an active targeting mode to

109 In contrast, PLGA-NP lutein had a lower uptake and secretion of lutei

110 The P2Ns outclass conventional PLGA-GA nanosystems in cellular uptake using caco-2 inte

111 We use poly(lactide-co-glycolide) copolymer (PLGA) fiber microfilaments as a floating scaffold to gen

112 Here, shape-defined PLGA microPlates (muPLs) were realized for the sustained

113 then tested the system in vivo by delivering PLGA nanoparticles co-loaded with antisense-miRNA-21 and

114 types of microparticles made with different PLGA concentrations and molecular weights.

115 dition, separation of a mixture of different PLGAs has not been previously identified, especially whe

116 A good solvent dissolves PLGAs with all L:G ratios ranging from 50:50 to 100:0.

117 A semi-solvent dissolves PLGAs with only certain L:G ratios.

118 due to a faster shell formulation, enabling PLGA microparticles to entrap more naltrexone into the s

119 The fluorescent PLGA-GA NS exhibited significant intestinal transport an

120 on, 144-fold more specific than observed for PLGA nanoparticles of similar size, polydispersity, zeta

121 ngs in analytical methods typically used for PLGA.

122 degradation and drug release mechanism from PLGA microspheres embedded in a PVA hydrogel.

123 The drug release profile from PLGA NMP was tri-phasic, being sustained over 5days.

124 Furthermore, PLGA NP formulation totally prevented bevacizumab system

125 The lack of generic PLGA products is partly due to difficulties in reverse e

126 Glu-PLGA is a branched (also known as star-shaped) polymer a

127 tion of the relevant parameters defining Glu-PLGA, such as the branching number, and the presence of

128 or, was tracked through the synthesis of Glu-PLGA by both (13)C NMR and enzymatic analysis.

129 to determine the branching parameters of Glu-PLGA extracted from Sandostatin LAR, as well as Glu-PLGA

130 GPC-4D enabled characterization of Glu-PLGA in its concentration, absolute molecular weight, hy

131 y were developed for characterization of Glu-PLGA with the lactide:glycolide (L:G) ratio of 55:45 use

132 r weight to <4 for the majority (94%) of Glu-PLGA.

133 characterize the branching parameters of Glu-PLGA.

134 mination of glucose within glucose-PLGA (Glu-PLGA) branched polymers.

135 Glucose-initiated PLGA (Glu-PLGA) has been used in Sandostatin(R) LAR Depot (octreot

136 tracted from Sandostatin LAR, as well as Glu-PLGAs obtained from three different manufacturers.

137 were also used to distinguish different Glu-PLGAs.

138 ethods indicate that the branch units of Glu-PLGAs extracted from Sandostatin LAR range from 2 (i.e.,

139 can also be used for characterization of Glu-PLGAs made of different L:G ratios.

140 non-linear PLGA, such as star-shaped glucose-PLGA, has been difficult due to the shortcomings in anal

141 the determination of glucose within glucose-PLGA (Glu-PLGA) branched polymers.

142 c acid) (PLGA) and PLGA-polyethylene glycol (PLGA-PEG) polymers to generate sub-100nm nanoparticles w

143 actide-coglycolide)-b-poly(ethylene glycol) (PLGA-PEG) for gene delivery by a robust self-assembly me

144 delivery platform, (ii) polyethylene glycol-PLGA conjugate (PEG-PLGA, p) to help maintain an appropr

145 or its copolymer, polylactide-co-glycolide (PLGA), do not allow such optimization due to their termi

146 cle based on poly(D,L-lactide-co-glycolide) (PLGA) and chitosan (CHIT) for delivery of natural antimi

147 Here, we produce poly(lactide-co-glycolide) (PLGA) based microparticles with varying morphologies, an

148 ns, specifically poly(lactide-co-glycolide) (PLGA) based systems, have been used to deliver drugs sys

149 Poly (lactide-co-glycolide) (PLGA) has been used for making injectable, long-acting d

150 Poly(lactide-co-glycolide) (PLGA) has been used in many injectable, long-acting depo

151 implants of poly(D,l-lactide-co-glycolide) (PLGA) have been demonstrated for diverse biomedical appl

152 lations based on poly(lactide-co-glycolide) (PLGA) have been used clinically since 1989.

153 perties of a poly(d,l-lactide-co-glycolide) (PLGA) matrix, thereby altering the drug release behavior

154 ion, electrospun poly (lactic-co-glycolide) (PLGA) mats, which have excellent biocompatibility and me

155 the size of poly(D,L-lactide-co-glycolide) (PLGA) microparticles produced by diverse microfluidic sy

156 altrexone-loaded poly(lactide-co-glycolide) (PLGA) microparticles were prepared using an in-line homo

157 of cryo-ground poly (lactide-co-glycolide) (PLGA) nanofibres (CPN) were incorporated into PNA hydrog

158 apsulated in poly(d,l-lactide-co-glycolide) (PLGA) NPs were used as the vaccine formulation.

159 ydrates-modified poly(lactide-co-glycolide) (PLGA) or poly(lactide-coglycolide)-b-poly(ethylene glyco

160 ons comprised of poly(lactide-co-glycolide) (PLGA) requires assays of the relevant properties of poly

161 Poly (d,l-lactide co-glycolide, PLGA)-based NPs loaded with a near-infrared dye as a mar

162 amine to the brain via ascorbic acid grafted PLGA-b-PEG nanoparticles (NPs) using SVCT2 transporters

163 ctives to the brain by ascorbic acid grafted PLGA-b-PEG NPs is a promising approach.

164 ic-co-glycolic acid)/poly(L-lactic acid) (HA-PLGA/PLLA) scaffolds.

165 'Taller' particles realized with higher PLGA concentrations encapsulated more drug reaching on a

166 Immunologically, PLGA-KAg vaccine irrespective of not significantly boost

167 array data suggested a mechanism of impaired PLGA degradation and intestinal acidification confirming

168 In PLGA-KAg vaccinated and heterologous SwIV H1N1 challenge

169 en-fluorescent dye) diffusion coefficient in PLGA.

170 owever, there are only 19 different drugs in PLGA formulations approved by the U.S.

171 combinant GET-RUNX2 protein) encapsulated in PLGA microparticles (MPs), we demonstrate that human mes

172 ted SwIV H1N2 antigens (KAg) encapsulated in PLGA nanoparticles (PLGA-KAg) were prepared, which were

173 5-FU was first entrapped in PLGA core by solvent evaporation technique followed by c

174 on of aqueous leuprolide/gelatin solution in PLGA 75/25 acid capped (13 kDa Mw) dissolved in methylen

175 ncorporated and approved for clinical use in PLGA-based formulations.

176 a drug product and characterizing individual PLGAs.

177 s isolation and identification of individual PLGAs from a complex mixture that is critical for the qu

178 , has been applied for separating individual PLGAs in a given depot formulation, leading to analysis

179 he hypothesis, this study shows that inhaled PLGA particles of sildenafil can be administered, as a s

180 Glucose-initiated PLGA (Glu-PLGA) has been used in Sandostatin(R) LAR Depo

181 A generic injectable PLGA product is required to establish qualitative and qu

182 further slowed by incorporating CPX-Zn into PLGA NPs as compared to the CPX NS with release half tim

183 A high molecular weight (148 kDa) PLGA at various concentrations was used to generate oil-

184 drug-loaded microspheres (PLGA-PEG_PGS-LHRH, PLGA-PEG_PTX-LHRH) is shown to result in greater reducti

185 Characterization of non-linear PLGA, such as star-shaped glucose-PLGA, has been difficu

186 adsorbed and/or encapsulated cationic lipid-PLGA hybrid nanoparticles; we designated antigen-adsorbe

187 ture design of vaccines using cationic lipid-PLGA nanoparticles.

188 After 14 days, bevacizumab-loaded PLGA NP demonstrated a reduction in the tumor growth acc

189 und in the brain just for bevacizumab-loaded PLGA NP group, after 14 days of formulation administrati

190 On the other hand, bevacizumab-loaded PLGA NP were able to increase the penetration (higher Cm

191 rapeutic and sustained action by drug loaded PLGA-b-PEG-Asc NPs than free drugs and drug loaded plain

192 studies also showed that all the drug-loaded PLGA-PEG microspheres for the localized and targeted tre

193 miRNA-loaded PLGA-NP were internalized in HCC cells and anti-apoptoti

194 mechanism compared to small molecule loaded PLGA microsphere products.

195 This work suggests that multi-loaded PLGA MSs present a novel therapeutic approach in the man

196 we describe the development of multi-loaded PLGA-microspheres (MSs) incorporating three recognised n

197 Peptide loaded PLGA microsphere products are more complex in terms of m

198 s study, model drug (vitamin D3, VD3)-loaded PLGA nano- and microparticles (NMP) were prepared by a s

199 platform generated monodisperse VEGF-loaded PLGA microcarriers with size-dependent release patterns.

200 Compared to free lutein, PLGA-NP increased the maximal plasma concentration (Cmax

201 In comparison with micellized lutein, PLGA-NP lutein improved the Cmax in rat plasma by 15.6-f

202 G/chitosan NPs, but not improved by lycopene/PLGA/chitosan NPs.

203 PTX-MB@PLGA NPs showed an IC(50) of 78 mug mL(-1) and 44.7+/-4.

204 -glycolic acid) (PLGA) nanoparticles (PTX-MB@PLGA NPs).

205 Melatonin-PLGA-PLL-Trolox nanoparticle as named as PolyRad was syn

206 om 50% to 10% and 2% for the 5, 10 and 20 mg PLGA configurations, respectively.

207 se from conjugated drug-loaded microspheres (PLGA-PEG_PGS-LHRH, PLGA-PEG_PTX-LHRH) is shown to result

208 of mice fed with chow containing Sub-A-mPEG-PLGA (0.2 mg Sub-A/g chow) (n = 9) compared to 31.9% in

209 The microencapsulated Sub-A-mPEG-PLGA showed significantly increased protection against a

210 e glycol)-b-poly(lactide-co-glycolide) (mPEG-PLGA) GRFT NPs.

211 (D,L-lactic-co-glycolic acid) nanoparticles (PLGA NP) were developed and intranasally administrated i

212 ns (KAg) encapsulated in PLGA nanoparticles (PLGA-KAg) were prepared, which were spherical in shape w

213 Conventional characterizations of PLGA used in a formulation rely on measuring the molecul

214 that is critical for the quality control of PLGA formulations, as well as reverse engineering for ge

215 mi-solvents which exhibit varying degrees of PLGA solubility depending on the L:G ratio of the polyme

216 owth was observed after systemic delivery of PLGA nanoparticles containing short PNA probes in vivo i

217 oxicity associated with systemic delivery of PLGA NPs containing short PNA probes in the mice.

218 ans-/intramucosal and lymph-node delivery of PLGA-PEG nanoparticles was demonstrated in a porcine mod

219 elatively wide particle size distribution of PLGA NMP was shown to be important in producing a compac

220 ction efficiency and uniform distribution of PLGA NPs containing short PNA probes in the cytoplasm.

221 A comprehensive evaluation of PLGA nanoparticles (NPs) containing short PNA probes sho

222 lease at low pH and with co-incorporation of PLGA.

223 ortant implications for the investigation of PLGA use in metabolically-compromised clinical and exper

224 he characterization of surface morphology of PLGA microparticles, as it is a manifestation of the for

225 ine +0.02% Tween 80 pH7.4, including rate of PLGA hydrolysis, mass loss and water uptake.

226 itative and quantitative (Q1/Q2) sameness of PLGA to that of a reference listed drug (RLD) to obtain

227 The particle size of PLGA NMP ranged from 300nm to 3.5mum and they retained t

228 Our results suggest that size of PLGA NPs can be used to tune delivery to certain tissues

229 , if a formulation has more than one type of PLGA, especially when they have similar molecular weight

230 ulation, leading to analysis of each type of PLGA.

231 polymers and a mechanistic understanding of PLGA microparticles formation.

232 e lack of a clear molecular understanding of PLGA polymers and a mechanistic understanding of PLGA mi

233 ainly due to the incomplete understanding of PLGA polymers and the various variables involved in the

234 An in depth understanding of PLGA polymers is critical for development of depot formu

235 Despite frequent use of PLGA, however, its characterization has been limited to

236 a simple, practical bench-top separation of PLGAs of varying L:G ratios.

237 we present a novel antimiR strategy based on PLGA nanoparticle delivered short PNA probes for potenti

238 the method's applicability was evaluated on PLGA nanoparticles and human plasma.

239 mportant for further development of not only PLGA depot formulations with controllable drug release k

240 for complex drug products such as parenteral PLGA microspheres with multiphasic drug release characte

241 ol)-block-poly(lactic-co-glycolic acid) (PEG-PLGA) copolymers have been used successfully for targete

242 e glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) microparticles were engineered to release TGF-beta

243 (ii) polyethylene glycol-PLGA conjugate (PEG-PLGA, p) to help maintain an appropriate level of polari

244 acid (FTA) loaded (lipid-cationic) lipid-PEG-PLGA hybrid nanoparticles (HNPs) after IN application in

245 l)-b-poly(lactic-co-glycolic acid); PLGA-PEG-PLGA) for increasing the retention of RNA nanoparticles

246 mplementary to the CNA sequence, whereas PEG-PLGA alone shows minimal DNA loading, and non-complement

247 RNA encapsulated, GalNAc decorated PEGylated PLGA nanoconjugates (NCs) viz., GalNAc@PEG@siRNA-PLGA we

248 hen formulated as dual-drug loaded PEGylated PLGA nanoparticles (EGCG/AA NPs).

249 colic Acid-Coated beta-Tricalcium Phosphate (PLGA-beta-TCP), for ARP purposes [Group A] compared to f

250 PHB or PLA/PLGA as encapsulating material in the production of nano

251 sc NPs than free drugs and drug loaded plain PLGA as well as PLGA-b-mPEG NPs.

252 xpressing NIH/3T3 cells as compared to plain PLGA and PLGA-b-mPEG NPs.

253 recent report, we have developed a poloxamer-PLGA nanoformulation loaded with elvitegravir (EVG), a c

254 Next, the biocompatible polymers PLGA-PEG-A were synthesized and used as base to conjugat

255 Thus, we prepared porous PLGA particles of sildenafil using a water-in-oil-in-wat

256 (ANN) models that are capable of predicting PLGA particle sizes produced by different microfluidic s

257 Flash nanoprecipitation was used to prepare PLGA nanoparticles (NPs) loaded with CPXZn.

258 The in-line approach produced PLGA microparticles with a highly reproducible size dist

259 PTX-PLGA-CSNP-RGD displayed favorable physicochemical proper

260 PTX-PLGA-CSNP-RGD showed less toxicity in lung fibroblasts t

261 san was synthesized and then coated onto PTX-PLGA nanoparticles prepared by emulsion-solvent evaporat

262 The PTX-PLGA-CSNP-RGD system showed increased uptake via integri

263 expression showed negligible toxicity to PTX-PLGA-CSNP-RGD, at equivalent drug concentrations used in

264 e optimized to prepare commercially relevant PLGA microsphere formulations for delivery of peptides,

265 ble poly(lactic-co-glycolic acid) scaffolds (PLGA), and hydroxyapatite powder (HA) were used to mimic

266 number of star-shaped PLGAs, and to separate PLGAs based on L:G ratios regardless of the molecular we

267 to develop new assay methods for separating PLGAs possessing different L:G ratios when used in a dru

268 o determine the branch number of star-shaped PLGAs, and to separate PLGAs based on L:G ratios regardl

269 GalNAc@PEG@siRNA-PLGA NCs were characterized for size, bioavailability, t

270 nanoconjugates (NCs) viz., GalNAc@PEG@siRNA-PLGA were engineered and their synergistic antitumor eff

271 leased a 3-fold larger mass of thrombin than PLGA particles loaded only with thrombin.

272 Taken together, our study demonstrates that PLGA-CSNP-RGD is a promising nanoplatform for integrin t

273 Our results show that PLGA nanoparticles accumulate and cause gut acidificatio

274 These results suggest that PLGA nanoparticles can be used as a delivery system for

275 The PLGA polymer, when emulsified in Pluronic F127/dextran A

276 ly, the muPL height from 5 to 10 mum and the PLGA mass from 1 to 5, 10 and 20 mg.

277 slower release from the zinc complex and the PLGA NPs, resulted in a 5-fold dose reduction compared t

278 s were used as an ionic "bridge" between the PLGA and DSP.

279 , radical-mediated process that degrades the PLGA nanoparticles and releases the molecule.

280 Increasing the PLGA concentration from 5.58% to 16.85% showed a corresp

281 The internal structure of the PLGA microspheres was evaluated using low temperature sc

282 nor were controlled by the bioerosion of the PLGA microspheres.

283 of infectious challenge virus in most of the PLGA-KAg vaccinated pig lung airways were observed.

284 Depending on the PLGA concentration, the particles either formed a core-s

285 ents identified in this study increase their PLGA solubility as the L:G ratio increases, i.e., the la

286 As these PLGA-encapsulated EtNBS nanoparticles are capable of pen

287 nactivated influenza virus delivered through PLGA-NPs reduced the clinical disease and induced cross-

288 and altered distribution profile compared to PLGA NS in vivo.

289 ciated with the use of FDBA+RACD compared to PLGA-beta-TCP alone, both ARP-SG approaches rendered com

290 triaxial fibers in comparison with uniaxial PLGA (50:50) and coaxial PLGA (50:50) (sheath)-gelatin (

291 not adequate for characterization of unique PLGA polymers, such as branched PLGA.

292 rogelators also served to clot blood, unlike PLGA particles loaded with thrombin.

293 While unloaded PLGA MPs inherently increase levels of pro-inflammatory

294 TCIN encapsulation using PLGA coated with CHIT enhanced its antimicrobial activit

295 ug into the different polymers or by varying PLGA:PCL polymer ratios.

296 chemotherapeutic potential of double walled PLGA-chitosan biodegradable nanogel entrapped with 5-flu

297 ere prepared with different molecular weight PLGA polymers (approximately 25 and 7 kDa) to achieve di

298 Pigs vaccinated twice with PLGA-KAg via intranasal route showed increased antigen s

299 nt amounts of DNA can be encapsulated within PLGA-containing nanoparticles through the use of a new s

300 ce of CPX from CPX NS, CPX-Zn NS, and CPX-Zn PLGA NPs was also assessed.